Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...

Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...

Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...